Clostridium Difficile-Associated Disease

Study shows warfarin effectiveness not inhibited by Alinia in patients with CDAD

Published in Hepatitis Weekly, January 2nd, 2006

Romark Laboratories announced a clinical study of Alinia (nitazoxanide) for treating Clostridium difficile-associated disease (CDAD) showed that administration of Alinia does not interact with warfarin, a drug that is commonly used by patients affected by CDAD.

The only two treatments available for CDAD in the United States are metronidazole and vancomycin. Metronidazole has been the standard of care for CDAD, but the rate of response to metronidazole is reported to have declined significantly in recent years. Vancomycin is typically reserved because of its cost and the risk of selecting vancomycin-resistant bacteria.

Romark recently completed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry